Last updated: February 20, 2026
Who Manufactures Brukinsa?
Brukinsa (zanubrutinib) is developed by BeiGene, a biotechnology company specializing in oncology treatments. It is an oral Bruton's tyrosine kinase (BTK) inhibitor approved for treating specific hematologic cancers.
Authorized Suppliers and Distributors
Primary Manufacturing Company
- BeiGene Ltd. produces Brukinsa, manufacturing the drug in their facilities compliant with Good Manufacturing Practices (GMP). The company's manufacturing sites are located in China, with distribution channels established globally.
Approved Distribution Channels
- BeiGene's Direct Distribution: BeiGene supplies Brukinsa directly to healthcare providers in certain regions via their distribution network.
- Authorized Distributors: Several regional and global pharmaceutical distributors handle Brukinsa sales, including:
- McKesson
- Cardinal Health
- AmerisourceBergen
Regional and Country-Specific Suppliers
- United States: BeiGene has obtained FDA approval; distribution is primarily through authorized distributors like McKesson and Cardinal Health.
- European Union: Supplied via BeiGene's distribution partners in Europe, compliant with EMA regulations.
- China: BeiGene directly supplies in China, where it holds the manufacturing and marketing rights.
Supply Chain Overview
- BeiGene maintains control over the manufacturing process and collaborates with third-party logistics providers for distribution.
- The company ensures supply chain security through validated delivery channels in each region.
- Brukinsa is available through hospital formularies, specialty pharmacies, and direct hospital supply channels.
Sales and Supply Data
- BeiGene reported increased production capacity in 2022 to meet global demand.
- As of 2023, the drug is available in over 20 countries, with more markets under review for approval.
Supply Risks
- Manufacturing relies on BeiGene's facilities in China, which could be affected by regional regulations or disruptions.
- Supply chain complexities exist due to global distribution, especially amid trade restrictions or logistical issues.
Key Points
- No independent third-party manufacturers are authorized to produce Brukinsa outside BeiGene's facilities.
- Suppliers in various regions act as licensees or authorized distributors, not independent manufacturers.
- The drug's supply depends on BeiGene's capacity and regional logistics infrastructure.
Summary Table: Brukinsa Supply Details
| Aspect |
Details |
| Manufacturer |
BeiGene Ltd. (China) |
| Approved Distributors |
McKesson, Cardinal Health, AmerisourceBergen |
| Regions Covered |
North America, Europe, China, select Asian markets |
| Production Sites |
BeiGene facilities in China |
| Supply Chain Control |
Direct from BeiGene & authorized partners |
| Global Availability |
20+ countries (2023) |
Final Notes
- Ongoing capacity expansion at BeiGene indicates increased availability.
- No independent third-party manufacturers currently approved.
- Timely supply depends on BeiGene's manufacturing and distribution efficiency.
Key Takeaways
- BeiGene is the sole manufacturer of Brukinsa.
- Distribution in major markets is through authorized international and regional distributors.
- The supply chain hinges on BeiGene's production capacity and logistics providers.
- Regional approvals influence the availability and supply stability.
FAQs
1. Are there any third-party companies manufacturing Brukinsa?
No, BeiGene holds exclusive manufacturing rights. All global supply is produced at their facilities.
2. How does Brukinsa reach healthcare providers?
Through BeiGene’s direct supply chain and authorized distributors such as McKesson and Cardinal Health.
3. Is Brukinsa available in Europe?
Yes, through BeiGene’s regional partners compliant with EMA regulations.
4. What risks affect the supply of Brukinsa?
Regional manufacturing disruptions, trade restrictions, and logistical challenges can impact supply.
5. Can Brukinsa be imported from China to other markets?
Importation depends on regional approvals and import regulations. It is primarily supplied through authorized channels in each market.
References
- BeiGene. (2022). Brukinsa (zanubrutinib) prescribing information.
- Food and Drug Administration. (2023). Brukinsa approval details.
- European Medicines Agency. (2023). Brukinsa authorization records.
- Industry supply chain reports. (2023). Global oncology drug distribution overview.
(numbering of references is for referencing purposes only)
